Bio-Rad Laboratories Inc Class A

BIO: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
^>SLOCK|J!?LOCK|F<@m!jR

Bio-Rad Earnings: Guidance for 2026 Pushes Back Timing for Recovery in Revenue Growth

Bio-Rad reported fourth-quarter revenue growth of 1.7% at constant currency and non-GAAP operating profit margin of 12%, or 180 basis points worse than last year's fourth quarter. The midpoints of 2026 guidance ranges are 1% revenue growth and 12.1% non-GAAP operating profit margin.

Sponsor Center